Abstract | BACKGROUND/AIM: PATIENTS AND METHODS:
Induction chemotherapy consisted of irinotecan i.v. and cisplatin i.v. and was administered on day 1 and day 8 of each cycle. Patients underwent two cycles of chemotherapy with a 3-week interval. In the absence of progressive disease, 66 Gy radiation was administered concurrently with etoposide on days 1 to 5 and 29 to 33, as well as with cisplatin on day 1, 8, 29, and 36. RESULTS: Twenty patients were enrolled between July 2007 and December 2009. This study was closed prematurely due to lack of efficacy in induction chemotherapy. The overall response rate was 45% [95% confidence interval (CI), 25 to 65%], which did not meet the upper limit for first stage rejection of the treatment. The rates of 3-year progression-free survival and overall survival were 17.1% (95% CI, 0 to 36.8%) and 25% (95% CI, 0.2 to 49.8%), respectively. The primary toxicities included neutropenia, diarrhea and fatigue. CONCLUSION: This study failed to demonstrate a benefit for induction chemotherapy which was characterized by suboptimal antitumor activity and was poorly tolerated, with excess treatment-related toxicity.
|
Authors | Hyun Chang, Se Hyun Kim, Byoung Chul Cho, Sang Hyun Yoon, Hye Ryun Kim, Chang Geol Lee, Joo Hang Kim |
Journal | Anticancer research
(Anticancer Res)
Vol. 32
Issue 8
Pg. 3515-21
(Aug 2012)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 22843939
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Irinotecan
- Cisplatin
- Camptothecin
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Camptothecin
(administration & dosage, analogs & derivatives)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology, radiotherapy)
- Cisplatin
(administration & dosage)
- Combined Modality Therapy
- Disease Progression
- Female
- Humans
- Irinotecan
- Lung Neoplasms
(drug therapy, pathology, radiotherapy)
- Male
- Middle Aged
- Neoplasm Staging
|